Q-omics provides the consensus-scored KLF14 profile across patient tissues and cancer cell-line models. KLF14 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KLF14 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, KLF14 RNA expression shows 15,145 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where KLF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF14 survival associations across molecular data types. KLF14 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF14 RNA expression–survival associations across cancer types. High KLF14 expression shows unfavorable associations in KIRP, BLCA, COAD, LUAD and STAD, but favorable associations in LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for KLF14 RNA expression.
This table summarizes KLF14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KLF14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF14 shows lower tumor expression in KIRC, BRCA, UCEC and KICH and higher tumor expression in HNSC and KIRP. The KIRC box plot shows higher KLF14 RNA expression in normal versus tumor tissue (log2 FC = −0.117, t-test p < 0.001).
This table shows molecular features associated with KLF14 in patient tissues and cancer cell lines. In patient samples, KLF14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
